Ionis Releases Data Update from Phase 2 Study in Infants with SMA
Ionis Pharmaceuticals provided an update on its ongoing open-label Phase 2 clinical study of nusinersen in infants with spinal muscular atrophy (SMA) at the American Academy of Neurology (AAN) meeting. The data reported show that there have been no new events, as defined by progression to permanent ventilation or death, in the study since December […]
Ionis Releases Data Update from Phase 2 Study in Infants with SMA Read More »